The following undesirable phenomena were observed during treatment with the use of texamen at the following frequency:
Very often (> 1/10); often (> 1/100 - <1/10); not often (> 1/1000 - <1/100); rarely (> 1/10000 - <1/1000); very rarely (<1/10000), the frequency is unknown (the frequency can not be determined based on the available data).
The undesirable phenomena that can be observed against the use of teksamena in coated tablets include the following:
Not often (> 1/1000 - <1/100)
From the digestive system:
A burning sensation in the stomach, stomach pain, vomiting, nausea, diarrhea, constipation, flatulence and gastropathy, abdominal pain, stomatitis, anorexia, and liver dysfunction. With prolonged use in large doses - ulceration of the mucous membrane of the gastrointestinal tract), bleeding (gastrointestinal, gingival, uterine, hemorrhoidal), perforation of intestinal walls.
From the side of the cardiovascular system:
heart failure, tachycardia, increased blood pressure.
Rarely (> 1/10000 - <1/1000)
Allergic Reagents:
Rashes, itching, erythema and urticaria. Photodermatitis.
From the nervous system:
Headache, dizziness, drowsiness, depression, agitation, hearing loss, tinnitus, eye irritation, blurred vision.
From the genitourinary system:
Increase of urea nitrogen and creatinine in the blood.
From the hematopoiesis:
Agranulocytosis, leukopenia, rarely anemia, thrombocytopenia.
Co side of the hepatobiliary system:
Increase in activity of alanine transaminase, aspartate aminotransferase and gamma-glutamyltransferase and serum bilirubin level.
Laboratory indicators:
Hypercreatininaemia, hyperbilirubinemia, increased urea nitrogen concentration and activity of hepatic transaminases, prolonged bleeding time.
On the background of treatment, there may be mental disorders and metabolic disorders.
Very rarely (<1/10000): Stevens-Johnson syndrome, Lyell syndrome.
The undesirable phenomena observed on the part of the hemopoiesis system include a decrease in the level of hemoglobin and granulocytopenia.